Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alec

Indication
Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive

Other upcoming events for NUVL

Patent ExpiryPatent/Exclusivity Expiry: ALECENSA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alec — NUVL Phase 3 Readout | BioSniper